questionText: To ask the Secretary of State for Health and Social Care, when the Clinical Priorities Advisory Group next plans to consider funding for Abiraterone in a prioritsation round.
answerText: NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting...
heading: Abiraterone: Finance